Business Context and Reporting Period
Company: Aveanna Healthcare Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 17, 2025
Event: Entry into a Material Definitive Agreement (Refinancing Amendment) and Termination of a Material Definitive Agreement (Second Lien Credit Agreement).
Key Financial Metrics and Debt Structure
This filing details a significant restructuring of the Company's debt facilities. The filing does not provide revenue, profit, cash flow, or margin data.
| Facility Type | Previous Balance/Commitment | New Balance/Commitment | Maturity Date |
|---|---|---|---|
| Term Loans (First Lien) | $885,950,000 | $1,325,000,000 | September 17, 2032 |
| Revolving Credit Facility | $170,330,000 | $250,000,000 | September 17, 2030 |
| Second Lien Term Loan | $415,000,000 | $0 (Repaid) | N/A |
Interest Rates (Term & Revolving): Term SOFR + 3.75% or Base Rate + 2.75% (subject to step-downs based on leverage ratios).
Amortization: 1.00% per annum on Term Loans.
Original Issue Discount: 99.75% of par.
Material Changes Versus Prior Period
- Debt Consolidation: The Company refinanced its existing First Lien Term Loans and fully repaid its Second Lien Term Loan ($415 million) using proceeds from new incremental term loans.
- Increased Capacity: Total Term Loan principal increased by $439,050,000. Revolving credit commitments increased by $79,670,000.
- Extended Maturities: The new Term Facility matures in 2032 and the Revolving Facility in 2030, extending the debt profile compared to the prior agreements.
- Fee Structure: New commitment fees of 0.50% per annum on undrawn revolving amounts, with potential step-downs to 0.375% and 0.250% based on leverage ratios.
Guidance, Outlook, and Risks
Use of Proceeds: Proceeds were utilized to refinance existing term loans, repay the Second Lien Term Loan, pay accrued interest, and fund working capital and general corporate purposes.
Covenants: Interest rate margins and commitment fees are subject to step-downs if the Consolidated First Lien Net Leverage Ratio falls below specific thresholds (3.90:1.00 and 3.40:1.00).
Risks: The filing notes that the description of the agreement is qualified by reference to the full text of the Refinancing Amendment (Exhibit 10.1). The filing does not contain specific forward-looking guidance on revenue or earnings.
Investor Verification Checklist
- Verify the exact Consolidated First Lien Net Leverage Ratio as of the last fiscal quarter to determine current interest rate margins.
- Review Exhibit 10.1 for specific covenants, prepayment penalties, and conditions precedent not detailed in the summary.
- Confirm the impact of the $439 million incremental term loan on the Company's overall leverage and interest coverage ratios.
- Assess the liquidity position post-refinancing, specifically the availability under the new $250 million revolving facility.